Urothelial Carcinoma
Advertisement
Dr. Ghoreifi explains how results suggest feasibility with high rates of pathological downstaging and complete response.
Dr. Gomella and Ambinder provide a comprehensive overview of the growing and changing treatment landscape for NMIBC.
Dr. Samuel Gold shares some perspective on the impact of disease recurrence on HRQoL after radical cystectomy.
Dr. John Gore offers interesting data from the CISTO study, favoring radical cystectomy for recurrent high-grade NMIBC.
Dr. Joseph Jacob shares the latest 1-year durability and PROs related to TAR-200 for BCG-unresponsive high-risk NMIBC.
Dr. Jayram highlights the updates in the ADVANCED-2 study: TARA-002 for patients with high-grade NMIBC.
Global shortages of BCG have led to the exploration of alternative therapies for HR non-muscle invasive bladder cancer.
Consolidative surgery after EVP shows feasibility and strong pathologic response rates in advanced urothelial carcinoma.
[68Ga]-FAPI-PET/MRI and [18F]-FDG-PET/CT share similar diagnostic accuracy for tumor staging in patients with MIBC.
Interim data may support the use of light-activated TLD-1433 photodynamic therapy for patients with BCG–unresponsive NMIBC.
N-803 plus BCG delivers sustained complete responses and high PFS in BCG-unresponsive bladder CIS, 2025 AUA data show.
Dr. Roberto Contieri presented on the safety, tolerability, and efficacy of neoadjuvant mitomycin C in patients with NMIBC.
Drs. Koshkin and Nizam discuss how a longer treatment-free interval may predict benefit from pembrolizumab rechallenge.
Drs. Koshkin and Nizam break down recent research on pembro in patients with la/mUC who responded to first-course pembro.
Dr. Koshkin highlights emerging data on Nectin-4–targeted imaging and radiopharmaceuticals in urothelial cancer.
Dr. Koshkin shares an overview of FAP-targeted theranostics, including UCSF-led studies showing FAP PET imaging’s ability.
Dr. Grivas provides perspective of the long-term outcomes from the JAVELIN Bladder 100 trial as pertaining to older patients.
At the time of a pre-specified interim analysis, significant improvements in EFS and OS were seen.
Dr. Tyson discusses real-world decision-making around bladder-sparing options for BCG-unresponsive NMIBC.
Surgical resection of the primary tumor can provide survival benefits in certain patients with metastatic UTUC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.